Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Apr;56(4):509-17.
doi: 10.1136/gut.2006.105379. Epub 2006 Nov 2.

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

Jan M H Van den Brande  1 , Tamara C Koehler, Zuzana Zelinkova, Roelof J Bennink, Anje A te Velde, Fibo J W ten Cate, Sander J H van Deventer, Maikel P Peppelenbosch, Daniël W Hommes
Affiliations
Clinical Trial

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

Jan M H Van den Brande et al. Gut. 2007 Apr.

Abstract

Background: The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TNF and subsequently induces apoptosis of activated lamina propria T lymphocytes in patients with Crohn's disease in vitro.

Aim: To test whether the ability of rapid anti-TNF-induced apoptosis in the gut predicts the efficacy of anti-TNF treatment in inflammatory bowel disease.

Methods: (99m)Technetium-annexin V single-photon emission computer tomography (SPECT) was performed in 2 models of murine experimental colitis and in 14 patients with active Crohn's disease as assessed by the Crohńs Disease Activity Index (CDAI) to study the effect of anti-TNF treatment on apoptosis in the intestine during active colitis. Disease activity was evaluated 2 weeks after infliximab infusion using the CDAI (definition response: drop of >100 points).

Results: Colonic uptake of (99m)Tc-annexin V significantly increased in 2,4,6-trinitrobenzene sulphonate-induced colitis as well as in transfer colitis on administration of anti-TNF antibodies compared with a control antibody as determined with dedicated animal pinhole SPECT. In addition, uptake of (99m)Tc-annexin V significantly increased in patients with active Crohn's disease responding to infliximab treatment. Colonic (99m)Tc-annexin V uptake ratio (mean (SEM)) increased from 0.24 (0.03) to 0.41(0.07) (p<0.01), 24 h after infliximab infusion (5 mg/kg). A mean increase of 98.7% in colonic uptake of (99m)Tc-annexin V could be detected in 10 of the 14 responding patients (CDAI >100 points at week 2) compared with 15.2% in non-responding patients (p = 0.03). Analysis of the mucosal biopsy specimens identified lamina propria T cells as target cells undergoing apoptosis.

Conclusions: These in vivo observations support the notion that colonic uptake of (99m)Tc-annexin V correlates with clinical benefit of anti-TNF treatment and might be predictive of therapeutic success.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Comment in

References

    1. Papadakis K A, Targan S R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 20001191148–1157. - PubMed
    1. van Deventer S J. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease—the mechanisms of action of infliximab. Aliment Pharmacol Ther 199913(Suppl 4)3–8. - PubMed
    1. Black R A, Rauch C T, Kozlosky C J.et al A metalloproteinase disintegrin that releases tumour‐necrosis factor‐alpha from cells. Nature 1997385729–733. - PubMed
    1. Moss M L, Jin S L, Becherer J D.et al Structural features and biochemical properties of TNF‐alpha converting enzyme (TACE). J Neuroimmunol 199772127–129. - PubMed
    1. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 199210411–452. - PubMed

Publication types

MeSH terms